EE200300239A - Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks - Google Patents

Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks

Info

Publication number
EE200300239A
EE200300239A EEP200300239A EEP200300239A EE200300239A EE 200300239 A EE200300239 A EE 200300239A EE P200300239 A EEP200300239 A EE P200300239A EE P200300239 A EEP200300239 A EE P200300239A EE 200300239 A EE200300239 A EE 200300239A
Authority
EE
Estonia
Prior art keywords
rosuvastatin
treatment
familial hypercholesterolemia
heterozygous familial
heterozygous
Prior art date
Application number
EEP200300239A
Other languages
English (en)
Inventor
Raza Ali
Gerard Hutchinson Howard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300239(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300239A publication Critical patent/EE200300239A/et
Publication of EE05507B1 publication Critical patent/EE05507B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300239A 2000-11-22 2001-11-16 Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks EE05507B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
EE200300239A true EE200300239A (et) 2003-08-15
EE05507B1 EE05507B1 (et) 2012-02-15

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300239A EE05507B1 (et) 2000-11-22 2001-11-16 Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks

Country Status (35)

Country Link
US (1) US6858618B2 (et)
EP (1) EP1339409B1 (et)
JP (2) JP5062940B2 (et)
KR (1) KR100815042B1 (et)
CN (1) CN1268339C (et)
AR (1) AR031766A1 (et)
AT (1) ATE394103T1 (et)
AU (2) AU2002214165B9 (et)
BG (1) BG66009B1 (et)
BR (1) BR0115511A (et)
CA (1) CA2429263C (et)
CY (1) CY1110428T1 (et)
CZ (1) CZ301583B6 (et)
DE (1) DE60133921D1 (et)
DK (1) DK1339409T3 (et)
EE (1) EE05507B1 (et)
ES (1) ES2305118T3 (et)
GB (1) GB0028429D0 (et)
HK (1) HK1056691A1 (et)
HU (1) HUP0301380A3 (et)
IL (2) IL155919A0 (et)
IS (1) IS6819A (et)
MX (1) MXPA03004336A (et)
MY (1) MY134902A (et)
NO (1) NO326245B1 (et)
NZ (1) NZ525754A (et)
PL (1) PL365386A1 (et)
PT (1) PT1339409E (et)
RU (1) RU2294744C2 (et)
SI (1) SI1339409T1 (et)
SK (1) SK6212003A3 (et)
TW (1) TWI238720B (et)
UA (1) UA75614C2 (et)
WO (1) WO2002041895A1 (et)
ZA (1) ZA200303636B (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20060013861A1 (en) * 2004-05-26 2006-01-19 Kgk Synergize Inc. Functional foods comprising flavonoids and tocotrienols and methods thereof
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
JP4713574B2 (ja) 2005-02-22 2011-06-29 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CA2729769C (en) * 2008-07-08 2017-09-05 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
WO2014043706A1 (en) 2012-09-17 2014-03-20 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
JP2022534716A (ja) 2019-05-27 2022-08-03 イマティクス ユーエス，アイエヌシー． ウイルスベクターおよびその養子細胞療法における使用
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202245775A (zh) * 2021-02-01 2022-12-01 美商瑪德瑞高製藥公司 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
BG107811A (bg) 2004-03-31
PL365386A1 (en) 2005-01-10
DE60133921D1 (de) 2008-06-19
HK1056691A1 (en) 2004-02-27
MXPA03004336A (es) 2003-08-19
ZA200303636B (en) 2004-08-12
CN1630520A (zh) 2005-06-22
CA2429263A1 (en) 2002-05-30
KR100815042B1 (ko) 2008-03-18
IL155919A (en) 2009-09-01
AR031766A1 (es) 2003-10-01
JP5062940B2 (ja) 2012-10-31
CN1268339C (zh) 2006-08-09
GB0028429D0 (en) 2001-01-10
MY134902A (en) 2007-12-31
AU2002214165B9 (en) 2013-07-04
NO326245B1 (no) 2008-10-27
US6858618B2 (en) 2005-02-22
EP1339409B1 (en) 2008-05-07
JP2004522714A (ja) 2004-07-29
HUP0301380A2 (hu) 2003-10-28
TWI238720B (en) 2005-09-01
BR0115511A (pt) 2003-12-30
SK6212003A3 (en) 2003-11-04
SI1339409T1 (sl) 2008-08-31
CY1110428T1 (el) 2015-04-29
NO20032292D0 (no) 2003-05-21
ES2305118T3 (es) 2008-11-01
ATE394103T1 (de) 2008-05-15
DK1339409T3 (da) 2008-09-08
US20040072852A1 (en) 2004-04-15
WO2002041895A1 (en) 2002-05-30
NZ525754A (en) 2004-10-29
EE05507B1 (et) 2012-02-15
KR20030048479A (ko) 2003-06-19
IS6819A (is) 2003-05-19
UA75614C2 (uk) 2006-05-15
JP2010031047A (ja) 2010-02-12
CZ20031406A3 (cs) 2003-09-17
AU1416502A (en) 2002-06-03
BG66009B1 (bg) 2010-10-29
CZ301583B6 (cs) 2010-04-21
NO20032292L (no) 2003-07-17
AU2002214165B2 (en) 2006-12-14
EP1339409A1 (en) 2003-09-03
CA2429263C (en) 2009-03-17
RU2294744C2 (ru) 2007-03-10
PT1339409E (pt) 2008-07-07
IL155919A0 (en) 2003-12-23
HUP0301380A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
DK1185299T3 (da) Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease
DE60205514D1 (de) Wegwerfwindel
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
DE60029883D1 (de) Medizinischer Vernebler
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DE60043764D1 (de) Wegwerfwindel
DE60021475D1 (de) Wegwerfwindel
DE60223697D1 (de) Wegwerfwindel
FI20000863A (fi) Uusi hoitomenetelmä
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DE60030399D1 (de) Wegwerfwindel
NO20033205L (no) Terapeutiske kromanforbindelser
ID26300A (id) Benda penyerap sekali pakai
DK1443938T3 (da) Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
DE60039211D1 (de) Wegwerfwindel
NO20033804L (no) Karbamatforbindelser for behandling av smerte
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
DE60227963D1 (de) Behandlungssystem
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
FI4299U1 (fi) Saunasuodatin
ID30381A (id) Penggunaan arilalkanoilpiridazina
DK1493442T3 (da) Reboxetin til behandling af perifer neuropati
ITMI20000147A0 (it) Procedimeto per il trattamento di fanghi

Legal Events

Date Code Title Description
HD1A Correction of address
MM4A Lapsed by not paying the annual fees

Effective date: 20161116